JP2006506329A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506329A5
JP2006506329A5 JP2004516828A JP2004516828A JP2006506329A5 JP 2006506329 A5 JP2006506329 A5 JP 2006506329A5 JP 2004516828 A JP2004516828 A JP 2004516828A JP 2004516828 A JP2004516828 A JP 2004516828A JP 2006506329 A5 JP2006506329 A5 JP 2006506329A5
Authority
JP
Japan
Prior art keywords
pathogen
receptor
pharmaceutical composition
represented
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004516828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506329A (ja
JP5219329B2 (ja
Filing date
Publication date
Priority claimed from FI20021275A external-priority patent/FI20021275A0/fi
Priority claimed from FI20030564A external-priority patent/FI20030564A0/fi
Application filed filed Critical
Priority claimed from PCT/FI2003/000528 external-priority patent/WO2004002495A1/en
Publication of JP2006506329A publication Critical patent/JP2006506329A/ja
Publication of JP2006506329A5 publication Critical patent/JP2006506329A5/ja
Application granted granted Critical
Publication of JP5219329B2 publication Critical patent/JP5219329B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004516828A 2002-06-28 2003-06-30 下痢の予防又は治療用の医薬組成物 Expired - Fee Related JP5219329B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FI20021275A FI20021275A0 (fi) 2002-06-28 2002-06-28 Terapeuttiset koostumukset käytettäväksi ripulien ehkäisyyn tai hoitoon
FI20021275 2002-06-28
FI20030564A FI20030564A0 (fi) 2003-04-14 2003-04-14 Zoonoottisia Helicobacter-lajeja sitovia aineita ja niiden käyttö
FI20030564 2003-04-14
PCT/FI2003/000528 WO2004002495A1 (en) 2002-06-28 2003-06-30 Therapeutic compositions for use in prophylaxis or treatment of diarrheas

Publications (3)

Publication Number Publication Date
JP2006506329A JP2006506329A (ja) 2006-02-23
JP2006506329A5 true JP2006506329A5 (OSRAM) 2006-08-10
JP5219329B2 JP5219329B2 (ja) 2013-06-26

Family

ID=30001920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004516828A Expired - Fee Related JP5219329B2 (ja) 2002-06-28 2003-06-30 下痢の予防又は治療用の医薬組成物

Country Status (10)

Country Link
US (1) US20060014717A1 (OSRAM)
EP (2) EP1531832B1 (OSRAM)
JP (1) JP5219329B2 (OSRAM)
AT (1) ATE428430T1 (OSRAM)
AU (1) AU2003242799A1 (OSRAM)
DE (1) DE60327211D1 (OSRAM)
DK (1) DK1531832T3 (OSRAM)
ES (1) ES2649736T3 (OSRAM)
IN (1) IN2004KO01960A (OSRAM)
WO (1) WO2004002495A1 (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952121A0 (en) * 2002-10-17 2002-10-31 Alchemia Limited Novel carbohydrate based anti-bacterials
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
PT1675601E (pt) † 2003-10-13 2009-08-31 Nestec Sa Moderação do efeito de endotoxinas
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
PT1629850E (pt) 2004-08-24 2007-08-14 Nutricia Nv Composição nutricional que compreende a administração de oligossacarídeos indigeríveis
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DE602007006635D1 (en) 2006-02-10 2010-07-01 Nestec Sa Oligosaccharidmischung
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
JP5077623B2 (ja) * 2006-03-30 2012-11-21 Ｄｉｃ株式会社 カシュー油変性固形フェノール樹脂の製造方法とゴム組成物
EP2008096A2 (en) * 2006-04-03 2008-12-31 Massachusetts Institute of Technology Glycomic patterns for the detection of disease
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
FI20065800A0 (fi) * 2006-12-13 2006-12-13 Glykos Finland Oy Polyvalentit biokonjugaatit
FI20075030A0 (fi) * 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Menetelmä solujen modifioimiseksi
FI20070471A0 (fi) * 2007-06-13 2007-06-13 Glykos Finland Oy Ravinnelisäkompositiota
US20100196539A1 (en) * 2007-06-25 2010-08-05 Albertus Alard Van Dijk Novel prebiotics
EP2185931B1 (en) 2007-09-07 2013-07-10 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
AU2008324105B2 (en) * 2007-11-08 2014-01-30 Société des Produits Nestlé S.A. Use of oligosaccharides containing N-acetyllactosamine for maturation of immune responses in neonates
PT2265135T (pt) 2008-03-14 2018-02-21 Nestec Sa Mistura simbiótica
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
WO2009149149A1 (en) * 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
GB0817908D0 (en) 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
EP2345656B1 (en) * 2008-10-10 2018-05-02 The Noguchi Institute N-acetylglucosaminyl beta-linked monosaccharide derivative as a helicobacter pylori bacterium proliferation inhibitor
FI20080665A0 (fi) 2008-12-18 2008-12-18 Glykos Finland Oy Luonnollisen tyyppiset sakkaridikoostumukset
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
FI20105824A0 (fi) * 2010-07-26 2010-07-26 Suomen Punainen Risti Veripalv Veriryhmästatuksen käyttö IV
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
CA2822490C (en) 2010-12-31 2020-03-31 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US8795746B2 (en) 2011-02-16 2014-08-05 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
EP2707379A4 (en) 2011-05-13 2014-10-08 Glycosyn LLC USE OF PURIFIED 2'-FUCOSYLLACTOSIS, 3-FUCOSYLLACTOSIS AND LACTODIFUCOTETRAOSE AS PREBIOTICS
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
WO2013164652A2 (en) * 2012-05-04 2013-11-07 Ineb-Instituto De Engenharia Biomédica Microspheres
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
EP2857410A1 (en) * 2013-10-04 2015-04-08 Jennewein Biotechnologie GmbH Process for purification of 2´-fucosyllactose using simulated moving bed chromatography
CN103622901B (zh) * 2013-11-21 2016-01-20 广州立白企业集团有限公司 一种能调节皮肤微生态平衡的皮肤清洁剂组合物及其制备方法
WO2016007778A1 (en) 2014-07-09 2016-01-14 Midori Usa, Inc. Oligosaccharide compositions and methods for producing thereof
EP3177325B1 (en) * 2014-08-08 2020-04-01 GlaxoSmithKline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CA2973617A1 (en) 2015-01-26 2016-08-04 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
EP4209130A1 (en) 2015-01-26 2023-07-12 DSM Nutritional Products, LLC Oligosaccharide compositions for use animal feed and methods of producing thereof
US9492473B2 (en) * 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
RU2731154C2 (ru) 2015-03-05 2020-08-31 Сосьете Де Продюи Нестле С.А. Композиция для применения в улучшении консистенции или частоты стула у младенцев или детей младшего возраста
MX378680B (es) 2015-03-05 2025-03-11 Soc Des Produits Nestle S A Star Composiciones para usar en la prevencion o el tratamiento de infecciones/inflamaciones gastrointestinales en infantes o niños pequeños.
EP3964234A1 (en) 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
WO2016176484A1 (en) 2015-04-28 2016-11-03 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
CN105410913B (zh) * 2015-12-01 2018-06-01 辽宁三合酒业有限公司 一种壳寡糖口腔清洁含片的制备方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US20190160082A1 (en) 2016-08-04 2019-05-30 Nestec S.A. Nutritional compositions with 2fl and lnnt for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP7576375B2 (ja) 2017-11-03 2024-10-31 カレイド・バイオサイエンシズ・インコーポレイテッド グリカン調製物及び高アンモニア血症のための使用方法
CN108018805B (zh) * 2017-12-31 2018-12-04 江苏来德福汽车部件有限公司 一种太阳能的智能移动护栏
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
EP3833195A1 (en) * 2018-08-08 2021-06-16 Mars Incorporated Pet food products comprising oligosaccharides and methods of use
CN109212227B (zh) * 2018-09-07 2021-07-16 深圳格道糖生物技术有限公司 基于唾液特异糖蛋白糖链结构的肝病/肝硬化相关筛查、评估的产品及应用
AU2024364769A1 (en) 2023-10-19 2026-05-07 N.V. Nutricia Mixture of human milk oligosaccharides
WO2025083289A1 (en) 2023-10-19 2025-04-24 N.V. Nutricia Mixture of human milk oligosaccharides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225330A (en) * 1988-08-01 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic kit and diagnostic method utilizing carbohydrate receptors
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US5834423A (en) * 1994-07-15 1998-11-10 Taiyo Kagaku Co., Ltd. Pharmaceutical composition containing sialic acid derivatives
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
US6291435B1 (en) * 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
FI20010118A7 (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
US20040176320A1 (en) * 2001-06-29 2004-09-09 Jari Natunen Use of at least one glycoinhibitor substance

Similar Documents

Publication Publication Date Title
JP5219329B2 (ja) 下痢の予防又は治療用の医薬組成物
Newburg Human milk glycoconjugates that inhibit pathogens
Kunz et al. Health promoting aspects of milk oligosaccharides
Coppa et al. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris
Kobata Structures and application of oligosaccharides in human milk
Sharon Carbohydrates as future anti-adhesion drugs for infectious diseases
EP2318047B1 (en) Probiotics, secretory iga and infection
US20020019991A1 (en) Compositions containing an alpha 1,2-fucose linkage and uses thereof
EP1411952B1 (en) Use of at least one glycoinhibitor substance against infectious diseases
Kelly et al. Nutritional influences on interactions between bacteria and the small intestinal mucosa
RU2306140C2 (ru) НОВЫЕ РЕЦЕПТОРЫ ДЛЯ Helicobacter pylori И ИХ ПРИМЕНЕНИЕ
AU783876B2 (en) Novel helicobacter pylori-binding substances and use thereof
US20060122148A1 (en) High affinity receptors for helicobacter pylori and use thereof
JPS59176300A (ja) 治療または診断上有用な化合物および組成物
AU2002229792A1 (en) Novel receptors for Helicobacter pylori and use thereof
CA2591253A1 (en) Specific oligosaccharides of shigella flexneri serotypes 3a and x, their synthesis, compositions comprising them and their uses thereof
US20050220819A1 (en) Novel binding epitopes for helicobacter pylori and use thereof
Shah et al. Adverse host responses to bacterial toxins in human infants
CN1646554A (zh) 唾液酸化的碳水化合物
WO2004065400A1 (en) Novel binding epitopes for helicobacter pylori and use thereof
Hueso et al. Role of milk carbohydrates in preventing bacterial adhesion
Natunen Use of at least one glycoinhibitor substance
Divya et al. Impact Of Human Milk Oligosaccharide (HMO) In Neonates
Campus et al. ROLE OF HUMAN MILK CONSTITUENTS IN BLOCKING THE ADHERENCE OF ENTERIC PATHOGENS
CN1627949A (zh) 适合抑制哺乳动物感染的环聚糖